- Home
- BTBD vs CURX Comparison
BTBD vs CURX Comparison
Compare BTBD & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTBD | CURX |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 7.6M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BTBD | CURX |
|---|---|---|
| Price | $1.28 | $0.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.6K | ★ 2.7M |
| Earning Date | 03-30-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,038,307.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $3.61 |
| 52 Week High | $5.60 | $8.60 |
Technical Indicators
Market Signals| Indicator | BTBD | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 47.00 | 35.60 |
| Support Level | $1.15 | $0.27 |
| Resistance Level | $1.30 | $0.31 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 41.95 | 22.87 |
Price Performance
Historical ComparisonAbout BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.